Primary Myelofibrosis (PMF) Clinical Trial
Official title:
Jaktinib in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib
This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib. The experiment is divided into two parts: dose exploration and extended research.
dose exploration: It is planned to enroll about 6 subjects. According to the baseline value of platelet count at the time of enrollment, different doses (100mg Qd or 150mg Qd or 200mg Qd or 100mg Bid) of Jaktinib Hydrochloride Tablets will be Treated. The trial is in progress Adjust the dose according to relevant laboratory indicators. When at least one subject has a spleen volume reduction of ≥35% from the baseline, the sponsor and the investigator will jointly decide whether to enter the extended study part. Extended research: It is planned to enroll about 43 subjects, and the initial dosage of Jaktinib Hydrochloride Tablets is planned to be 100mg Bid. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03441113 -
Extended Access of Momelotinib in Adults With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT01558739 -
Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
|
Phase 4 | |
| Completed |
NCT00910728 -
Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
|
Phase 1 | |
| Completed |
NCT02101268 -
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
|
Phase 3 | |
| Completed |
NCT03136185 -
Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
|
Phase 1/Phase 2 | |
| Completed |
NCT02515630 -
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
|
Phase 2 | |
| Recruiting |
NCT03662126 -
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
|
Phase 2/Phase 3 | |
| Terminated |
NCT03935555 -
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
|
Phase 1 | |
| Recruiting |
NCT04878003 -
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
|
Phase 2 | |
| Available |
NCT04745637 -
Managed Access Programs for INC424, Ruxolitinib
|